Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics


Madrigal Pharmaceuticals, Inc. (MDGL): $107.94

1.13 (+1.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MDGL Stock Price Chart Interactive Chart >

Price chart for MDGL

MDGL Price/Volume Stats

Current price $107.94 52-week high $142.62
Prev. close $106.81 52-week low $97.00
Day low $106.40 Volume 135,900
Day high $108.34 Avg. volume 165,574
50-day MA $122.44 Dividend yield N/A
200-day MA $119.23 Market Cap 1.79B

Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio


Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.


MDGL Latest News Stream


Event/Time News Detail
Loading, please wait...

MDGL Latest Social Stream


Loading social stream, please wait...

View Full MDGL Social Stream

Latest MDGL News From Around the Web

Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences: 42nd Annual Goldman Sachs Global Healthcare Conference Fireside chat at 9:40 a.m. ET on Thursday, June 1

Yahoo | June 8, 2021

We're Interested To See How Madrigal Pharmaceuticals (NASDAQ:MDGL) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | May 24, 2021

Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference

WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 4:00 pm ET. The fireside chat will be webcast live and can be accessed in the Investor Relat...

Yahoo | May 21, 2021

Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com

Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Investing.com | March 4, 2021

Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We are pleased with the substantial progress the Company made in 2020, particularly in light of the significant challenges resulting from the COVID-19 pandemic,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “We completed enrollment in the Company’s Phase 3 MAESTRO-NAFLD-1 trial in less than 12 months, and we also made significant progress in enrollment of our Phase 3 MAESTRO-NASH trial.” Dr. Friedman continued, “We advanced the development of Madrigal’s commercial capabilities in 2020, with Remy Sukhija joining the Company as Senior Vice President and Chief Commercial Officer. R...

Yahoo | February 25, 2021

Read More 'MDGL' Stories Here

MDGL Price Returns

1-mo -19.87%
3-mo -7.55%
6-mo -12.14%
1-year 1.11%
3-year -64.10%
5-year 894.84%
YTD -2.91%
2020 22.02%
2019 -19.17%
2018 22.80%
2017 516.04%
2016 21.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7783 seconds.